On the morning of Thursday, March 7, the House Ways & Means Committee’s Subcommittee on Health held a hearing titled Promoting Competition to Lower Medicare Drug Prices. The hearing focused a great deal on the effect of patents in the pharmaceutical industry as they relate to pricing. Although some of the Republican membership of the subcommittee pointed out issues with various proposals to limit patent protections for drugmakers, the panel acted largely as a firing squad for patents. In his closing statement, Rep. Doggett expressed his dissatisfaction with the tenor of the day’s debate. “I view it as encouraging that there is bipartisan recognition of the serious problems so many Americans are facing with, really, prescription price gouging,” he said. “The question is whether we’ll have any bipartisan agreement on doing anything about it.”
The post House Health Subcommittee Holds Fractious Hearing on Drug Pricing and Patent Protections appeared first on IPWatchdog.com | Patents & Patent Law.
House Health Subcommittee Holds Fractious Hearing on Drug Pricing and Patent Protections
No Comments
Business
- This Week in D.C.: NASA Deep Space Exploration, Small Business and Innovation, and Transportation Sustainability
- Chief Judge Paul Michel: Patent Reform Progress is Likely, But We Must Stay Focused On the Big Picture
- Take Steps to Deter the Spy in Your Business
- Don’t Ignore the Flashing Caution Lights in the Drug Pricing Debate
- Proving a Negative Claim Limitation: A Tale of Three Nonprecedential Cases
Recent Posts
- This Week in D.C.: NASA Deep Space Exploration, Small Business and Innovation, and Transportation Sustainability
- Chief Judge Paul Michel: Patent Reform Progress is Likely, But We Must Stay Focused On the Big Picture
- Take Steps to Deter the Spy in Your Business
- Russia: Court Removes Candidate from Ballot for Social Network Post
- Don’t Ignore the Flashing Caution Lights in the Drug Pricing Debate